Raymond James & Associates Invests $254,000 in Grifols, S.A. (NASDAQ:GRFS)

Raymond James & Associates bought a new stake in shares of Grifols, S.A. (NASDAQ:GRFSFree Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 27,775 shares of the biotechnology company’s stock, valued at approximately $254,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Captrust Financial Advisors boosted its position in shares of Grifols by 153.5% in the 2nd quarter. Captrust Financial Advisors now owns 2,086 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 1,263 shares in the last quarter. Amundi boosted its position in shares of Grifols by 2,512.9% in the 4th quarter. Amundi now owns 3,632 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 3,493 shares in the last quarter. Signaturefd LLC boosted its position in shares of Grifols by 59.2% in the 2nd quarter. Signaturefd LLC now owns 4,222 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 1,570 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in shares of Grifols by 71.1% in the 2nd quarter. PNC Financial Services Group Inc. now owns 8,062 shares of the biotechnology company’s stock worth $74,000 after purchasing an additional 3,350 shares in the last quarter. Finally, Susquehanna International Securities Ltd. acquired a new stake in Grifols during the 1st quarter worth about $74,000. Institutional investors own 16.42% of the company’s stock.

Grifols Price Performance

Shares of Grifols stock opened at $8.39 on Wednesday. The company has a quick ratio of 0.75, a current ratio of 2.48 and a debt-to-equity ratio of 1.20. Grifols, S.A. has a twelve month low of $6.35 and a twelve month high of $12.15. The business has a 50-day moving average price of $9.33 and a 200 day moving average price of $9.34. The firm has a market cap of $5.77 billion, a PE ratio of 6.50, a P/E/G ratio of 0.22 and a beta of 0.60.

Wall Street Analysts Forecast Growth

Separately, JPMorgan Chase & Co. lifted their price target on Grifols from $10.00 to $10.50 and gave the stock a “neutral” rating in a research report on Tuesday, December 5th.

Check Out Our Latest Report on GRFS

Grifols Profile

(Free Report)

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada and internationally. The Biopharma segment provides plasma derivatives products, including Gamunex/Gamunex-C Immune Globulin Injection, Flebogamma Immune Globulin Intravenous, Xembify Immune Globulin Subcutaneous solution, HyperRAB Rabies Immune Globulin, Prolastin/Prolastin-C/Prolastin-C Liquid/Prolasplan/Prolastina/Pulmolast/Lynspad Alpha 1-Proteinase Inhibitor, Fanhdi and Alphanate, Antihemophilic Factor/von Willebrand factor Complex, Koate-DVI Antihemophilic Factor, Albutein/Albutein Flexbag/ Human Albumin Grifols/Plasbumin Albumin, and Vistaseal/Veraseal; and Tavlesse, a non-plasma derivative medicinal product.

Recommended Stories

Want to see what other hedge funds are holding GRFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Grifols, S.A. (NASDAQ:GRFSFree Report).

Institutional Ownership by Quarter for Grifols (NASDAQ:GRFS)

Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.